Trimetazidine as an Adjunct to Enhance Clopidogrel Response.
Condition(s):Platelet Dysfunction Due to DrugsLast Updated:December 2, 2019Completed
Hide Studies Not Open or Pending
Condition(s):Platelet Dysfunction Due to DrugsLast Updated:December 2, 2019Completed
Condition(s):AKI – Acute Kidney InjuryLast Updated:January 19, 2023Recruiting
Condition(s):Acute Respiratory Distress Syndrome; Covid19; Myocardial InjuryLast Updated:February 21, 2021Unknown status
Condition(s):Non-Alcoholic Fatty Liver DiseaseLast Updated:November 21, 2023Recruiting
Condition(s):Diabetes Mellitus; Angina, UnstableLast Updated:October 24, 2018Unknown status
Condition(s):Diabetes Mellitus, Type 2; Diabetic CardiomyopathiesLast Updated:September 27, 2022Recruiting
Condition(s):CardiotoxicityLast Updated:June 25, 2021Unknown status
Condition(s):Patients With INOCA(Ischemia and no Obstructive Coronary Artery Disease) Who Have Coronary Microvascular DysfunctionLast Updated:October 25, 2018Unknown status
Condition(s):Aluminum Phosphide PoisoningLast Updated:January 11, 2021Unknown status
Condition(s):Hypertrophic CardiomyopathyLast Updated:February 28, 2013Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.